Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings

Journal of Medical Economics

Volumn 16, Issue 4, 2013, Pages 566-574

  Hancock Howard, Rebecca L ^a   Feindel, Christopher M ^b   Rodes Cabau, Josep ^c   Webb, John G ^d   Thompson, Ann K ^e   Banz, Kurt ^f  

^a OPTUM   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d St Paul's and Vancouver General Hospitals   (Canada)

^e EDWARDS LIFESCIENCES   (United States)

^f Outcomes International   (Switzerland)

Author keywords

Aortic stenosis; Canada; Cost effectiveness; Transcatheter aortic valve replacement

Indexed keywords

AGED; AORTA STENOSIS; ARTICLE; CANADA; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; ENDOCARDITIS; FOLLOW UP; HEALTH CARE COST; HEART INFARCTION; HOME CARE; HOSPITAL COST; HOSPITAL PATIENT; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; NURSING CARE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; POSTOPERATIVE COMPLICATION; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SURVIVAL RATE; TRANSCATHETER AORTIC VALVE IMPLANTATION;

AORTIC VALVE STENOSIS; CANADA; COST-BENEFIT ANALYSIS; HEALTH SERVICES; HEART VALVE PROSTHESIS IMPLANTATION; HOSPITALIZATION; HUMANS; MODELS, ECONOMIC; PATIENT ACUITY; POSTOPERATIVE COMPLICATIONS; QUALITY-ADJUSTED LIFE YEARS; SURVIVAL ANALYSIS;

EID: 84875726377     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.770747     Document Type: Article

References (24)

1. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Emerging technologies list: percutaneous heart valve replacement. Ottawa: Government of Canada, 2005. Report No.: 28.
2. Lester SJ, Heilbron B, Gin K, et al. The natural history and rate of progression of aortic stenosis. Chest 1998;113:1109-14
3. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:1597-607
4. Reynolds MR, Magnuson EA, Lei Y, et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation 2011;124:1964-72
5. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edn. Ottawa: Government of Canada, 2006.
6. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012; 366:1696-704
7. Reynolds MR, Magnuson EA, Wang K, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis. Results from the Placement of Aortic Transcatheter Valves (PARTNER) trial (Cohort B). Circulation 2012; 125:1102-9
8. Statistics Canada. The Consumer Price Index. Ottawa: Government of Canada, 2010. Report No.: 62-001-X, vol. 89, no. 3.
9. Ontario Case Costing Initiative. Ontario guide to case costing. Province of Ontario, Canada: Ministry of Health and Long-Term Care, 2010.
10. Rodes-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. J Am Coll Cardiol 2010;55:1080-90
11. Ontario Ministry of Health and Long-Term Care. Schedule of Benefits: Physician Services under the Health Insurance Act. Ontario: 2010. http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/ physserv-mn.html. Accessed July 1, 2008.
12. Kolh P, Kerzmann A, Honore C, et al. Aortic valve surgery in octogenarians: predictive factors for operative and long-term results. Eur J Cardiothorac Surg 2007;31:600-6
13. Maillet JM, Somme D, Hennel E, et al. Frailty after aortic valve replacement (AVR) in octogenarians. Arch Gerontol Geriatr 2009;48:391-6
14. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81
15. Dewey TM, Brown DL, Das TS, et al. High-risk patients referred for transcatheter aortic valve implantation: management and outcomes. Ann Thorac Surg 2008;86:1450-6
16. Descoutures F, Himbert D, Lepage L, et al. Contemporary surgical or percutaneous management of severe aortic stenosis in the elderly. Eur Heart J 2008;29:1410-7
17. Neyt M, Van Brabandt H, Devriese S, et al. A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population. BMJ Open 2012;2:e001032
18. Watt M, Mealing S, Eaton J, et al. Cost-effectiveness of transcatheter aortic valve replacement in patients ineligible for conventional aortic valve replacement. Heart 2012;98:370-6
19. McGregor M, Esfandiari S. Transcatheter Aortic Valve Implantation (TAVI) at the MUHC: a Health Technology Assessment. Montreal: McGill University Health Centre, 2009. Report No.: 45
20. Thomas M, Schymik G, Walther T, et al. Thirty-day results of the SAPIEN aortic Bioprosthesis European Outcome (SOURCE) Registry: a European registry of transcatheter aortic valve implantation using the Edwards Sapien Valve. Circulation 2010;122:62-9
21. Wendt D, Eggebrecht H, Kahlert P, et al. [Experience and learning curve with transapical aortic valve implantation]. Herz 2009;34:388-97
22. British Columbia Ministry of Health, Medical Services Commission. Physician payment schedule, cardiology. British Columbia: Ministry of Health, 2011
23. Rajani R, Buxton W, Haworth P, et al. Prognostic benefit of transcatheter aortic valve implantation compared with medical therapy in patients with inoperable aortic stenosis. Catheter Cardiovasc Interv 2010;75:112-6
24. Saia F, Marrozzini C, Dall'ara G, et al. How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation? J Cardiovasc Med (Hagerstown) 2010;11:727-32